Alabama AG Demands Answers: Medical Establishment Caught in Stunning Contradiction on Child Gender Treatments

Alabama Attorney General Stephen Marshall is demanding the American Medical Association explain a glaring inconsistency that could violate state consumer protection laws: Why does the nation’s most powerful medical lobby still endorse puberty blockers and cross-sex hormones for children after admitting there’s insufficient evidence to support irreversible surgeries?

The evidence quality is identical. Both surgical and hormonal interventions rest on the same shaky foundation of low and very-low quality research. Yet the AMA continues championing drugs that can permanently sterilize children while backing away from the scalpel.

Marshall isn’t mincing words in his letter to AMA President John Whyte. He warned that the organization’s contradictory stance could be actively misleading families and healthcare providers across Alabama—potentially running afoul of laws prohibiting organizations from falsely representing that products or services have “uses, benefits, or qualities that they do not have.”

“We remain concerned that providers, patients, and their families in our States are being confused or misled by the AMA regarding the safety and efficacy of puberty blockers and cross-sex hormones to treat gender dysphoria in minors,” Marshall wrote.

The 30-Day Ultimatum

Marshall gave the AMA thirty days to answer pointed questions clarifying its position on pediatric gender treatments. The alternative? A formal investigation under Alabama’s consumer protection laws.

The threat carries weight. Marshall successfully defended Alabama’s law banning sex-change procedures for minors all the way through federal litigation—and in the process unearthed hundreds of pages documenting the deeply political forces driving the transgender medicine industry.

Those documents exposed how Biden administration official Richard “Rachel” Levine pressured the World Professional Association of Transgender Health to remove age minimums from clinical guidelines—prioritizing ideology over children’s safety.

Medical Establishment’s House of Cards Collapsing

The AMA’s recent reversal on surgical interventions represents a seismic shift. The organization now admits that “surgical interventions in minors should be generally deferred to adulthood” due to absence of “clear evidence” supporting their use.

That admission came on the heels of the American Society of Plastic Surgeons publishing a position statement recommending surgeons delay gender-related procedures until patients reach at least 19 years old. The ASPS went further, highlighting “substantial uncertainty” regarding long-term benefits and harms of puberty blockers and cross-sex hormones themselves.

The scientific foundation for the entire pediatric gender medicine regime is crumbling in real time.

The Question That Exposes Everything

Marshall poses the question that cuts to the heart of the matter: “If you agree that there is insufficient evidence to support using surgical interventions to treat gender dysphoria in minors—as your recent statement indicates—we do not understand how you can find that there is sufficient evidence to support using hormonal interventions to treat gender dysphoria in minors.”

The logic is ironclad. The evidence base is the same. The permanence of consequences can be identical.

“These interventions have not been shown to be any safer for children than sex-change surgeries are, and in fact may be all the more dangerous precisely because they are viewed as not as serious,” Marshall wrote. “But hormones can leave a child sterilized just as surely as surgery can.”

WPATH Guidelines: A Decade of Damaged Children

A 2025 Department of Health and Human Services report delivered a devastating assessment of the World Professional Association of Transgender Health guidelines that have served as the blueprint for pediatric gender medicine in America for over a decade.

The WPATH standards were “rated among the lowest in quality” and “have not been recommended for implementation by systematic reviews of guidelines,” according to the federal analysis.

Despite their complete lack of scientific trustworthiness, these discredited guidelines became the foundation supporting an entire medical infrastructure built around chemically and surgically altering gender-confused children.

Marshall views the AMA’s acknowledgment of insufficient evidence for surgeries as a “tacit acknowledgement” that WPATH’s standards fail to meet evidence-based medical standards—raising the question of why the AMA continues endorsing any interventions based on those same flawed guidelines.

Consumer Protection or Medical Malpractice?

The attorney general’s letter strategically frames the issue as potential consumer fraud—a novel legal approach that could have far-reaching implications beyond Alabama.

If major medical organizations are knowingly promoting treatments for children while lacking sufficient evidence of safety or efficacy, they may be violating fundamental consumer protection principles that apply to any entity offering goods or services to the public.

This isn’t about abstract medical ethics anymore. It’s about whether powerful institutions misled families about experimental treatments with life-altering consequences for their children.

The Reckoning Accelerates

Marshall’s aggressive challenge to the AMA represents the latest front in a broader reckoning over pediatric gender medicine sweeping across America and the developed world.

European countries that pioneered these interventions—including Sweden, Finland, and the United Kingdom—have dramatically restricted or eliminated them for minors after systematic evidence reviews found the promised benefits unsubstantiated and risks underappreciated.

Now American state attorneys general are demanding the same evidence-based accountability from a medical establishment that has prioritized political correctness over children’s wellbeing for far too long.

The AMA faces a stark choice: provide scientific justification for its contradictory positions within thirty days, or face the prospect of formal investigation for potentially misleading the public about experimental treatments administered to vulnerable children.

The clock is ticking. And the credibility of American medical institutions hangs in the balance.